Results 181 to 190 of about 22,335 (252)

Role of FibroScan in evaluating hepatic involvement in systemic amyloidosis: a single‐centre prospective pilot study

Internal Medicine Journal, EarlyView.
Abstract Background Amyloidosis encompasses a group of diseases characterised by extracellular deposition of misfolded protein fibrils, potentially leading to organ dysfunction. Liver involvement occurs via direct amyloid infiltration, common in immunoglobulin light chain (AL) amyloidosis, or congestive hepatopathy, more typical in transthyretin (ATTR)
M Tang, N Vootukuru, J Tjahyadi, D Clayton Chubb, H Jina, SB Ting, S Bloom, R Sawhney, S Gibbs, O. Niewiadomski   +9 more
wiley   +1 more source

Metabolic Dysfunction-Associated Steatotic Liver Disease and Kidney Transplant Outcomes. [PDF]

Kidney Int Rep
Yoon SY, El Bouzaidi Tiali S, Wing S, Davalan W, Jatana S, Slapcoff L, Nitulescu R, Rahme E, Nakhla M, Morin SN, Sebastiani G, Sapir-Pichhadze R.   +11 more
europepmc   +1 more source

Steatotic liver disease: Know your enemies

Clinical and Molecular Hepatology
openaire   +3 more sources

The role of C3 in steatotic liver disease

Immunobiology
Adrian Iliescu, Dien Nguyen, Robert Byrne, Gareth Fenn, Thomas Pembroke, Timothy Hughes, You Zhou   +6 more
openaire   +1 more source

Role of glucagon in metabolic diseases

Journal of Diabetes Investigation, EarlyView.
ABSTRACT Currently, diabetes is defined as “a chronic hyperglycemic state resulting from the absolute or relative insufficiency of insulin action,” emphasizing its characterization as an insulin‐related disease. However, glucagon dysregulation should also play a critical role in the pathophysiology of type 2 diabetes.
Tadahiro Kitamura, Yoko Tabei, Masaki Kobayashi   +2 more
wiley   +1 more source

Advances in quantitative ultrasound for metabolic dysfunction-associated steatotic liver disease diagnosis. [PDF]

Front Physiol
Ma Z, Liu B, Zhou S, Yang S, Sun X, Jiang X, Sun X.   +6 more
europepmc   +1 more source

Precision pathophysiology in steatotic liver disease

Clinical and Molecular Hepatology
Wonseok Lee, Da Kyung Hwang, Hyun Young Kim, David A. Brenner   +3 more
openaire   +1 more source

GLP‐1 RA Plus SGLT2i Versus Monotherapy in MASLD and Type 2 Diabetes: Three Pairwise Target Trial Emulations

Journal of Gastroenterology and Hepatology, EarlyView.
ABSTRACT Introduction Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) and sodium‐glucose cotransporter‐2 inhibitors (SGLT2is) have demonstrated cardiovascular and metabolic benefits individually; however, the comparative effectiveness of combination therapy versus monotherapy in patients with metabolic dysfunction‐associated steatotic liver ...
Mohanad A. Alkuwaiti, Faisal A. Al‐Harbi, Ahmed K. Alsaif, Ziyad M. AlSughayyir, Rayan Saleh Alsaud, Mohammed N. Aljabr, Ahmad K. Alanazi, Ahmad A. Alosaily, Abdulrhman K. Alabdulqader, Hamza Almusabeh, Rayyan F. Altemani, Ahmed Y. Azzam   +11 more
wiley   +1 more source

Distinct Roles of Myeloid- and Hepatocyte-PLA2G6 Deletion in Mice With Metabolic Dysfunction-Associated Steatotic Liver Disease. [PDF]

Liver Int
Li G, Staffer S, Tuma-Kellner S, Merle U, Chamulitrat W.   +4 more
europepmc   +1 more source

Treatment Goals for Primary Biliary Cholangitis, an Australian Perspective

Journal of Gastroenterology and Hepatology, EarlyView.
ABSTRACT Primary biliary cholangitis (PBC) is an autoimmune liver disease that targets the small intrahepatic bile ducts with diagnosis based on elevated serum alkaline phosphatase (ALP) levels and the presence of anti‐mitochondrial antibodies. Untreated, it may run a progressive course to cirrhosis and hepatic decompensation, at which point liver ...
Simone I. Strasser, Alexander J. Thompson, Rohit Gupta, John Lubel, Janine French, Beverly Sacks, Martin Weltman   +6 more
wiley   +1 more source